AR059192A1 - Composiciones coadyuvantes glicolipidicas - Google Patents

Composiciones coadyuvantes glicolipidicas

Info

Publication number
AR059192A1
AR059192A1 ARP070100334A ARP070100334A AR059192A1 AR 059192 A1 AR059192 A1 AR 059192A1 AR P070100334 A ARP070100334 A AR P070100334A AR P070100334 A ARP070100334 A AR P070100334A AR 059192 A1 AR059192 A1 AR 059192A1
Authority
AR
Argentina
Prior art keywords
compositions
glycolipid
weak acid
alkyl
modified
Prior art date
Application number
ARP070100334A
Other languages
English (en)
Inventor
Sangita Mediratta
Paul Joseph Dominowski
Ramasamy Mannar Mannan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR059192A1 publication Critical patent/AR059192A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265—Infectious rhinotracheitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18651—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composiciones y procedimientos de preparacion de soluciones madre de diluyente coadyuvante estable y soluciones coadyuvantes finales que comprenden glicolípidos, ácidos débiles, alcoholes, tensioactivos no ionicos y tampones. Dichas composiciones son estables durante un largo período sin floculacion. Son particularmente utiles en el suministro de diversas medicinas, incluyendo vacunas. Reivindicacion 1: Una composicion que comprende: a) un glicolípido de formula (1); en la que R1 y R2 son independientemente hidrogeno o radical alquilo saturado que tiene hasta 20 átomos de carbono; X es -CH2-, -O- o -NH-; R2 es hidrogeno o radical alquilo saturado o insaturado que tiene hasta 20 átomos de carbono; R3, R4 y R5 son independientemente hidrogeno, -SO42-, -PO42-, -CO-alquilo C1-10; R6 es L-alanilo, L-aIfa-aminobutilo, L-arginilo, L-asparginilo, L-aspartilo, L-cisteinilo, L-glutamilo, L-glicilo, L-histidilo, L-hidroxipropilo, L-isoleucilo, L-leucilo, L-lisilo, L-metionilo, L- ornitinilo, L-fenilalanilo, L-prolilo, L-serilo, L-treonilo, L-tirosilo, L-triptofanilo y L-valilo o sus isomeros D; en una forma de sal, en la que la forma de sal deriva de un ácido débil; b) un alcohol, en el que el alcohol es HO-alquilo C1-3; c) un ácido débil, en el que el ácido débil 1) está en exceso molar con respecto al contenido de glicolípido, y 2) es cualquier ácido que tenga un valor de pKa (el -log de Ka) entre 1,0 y 9,5 utilizando las tablas o valores estándar; d) un tensioactivo no ionico, en el que el tensioactivo no ionico es un agente que reduce la tension superficial del material que se disuelve en él y tiene un componente que es hidrofobo y otro componente que es hidrofilo. Reivindicacion 12: Una composicion de cualquiera de las reivindicaciones 1-11, que comprende adicionalmente un antígeno seleccionado del grupo, o cualquier combinacion de los mismos, constituido por herpesvirus bovino vivo modificado, virus sincitial respiratorio bovino vivo modificado y virus de la parainfluenza 3 vivo modificado.
ARP070100334A 2006-01-26 2007-01-25 Composiciones coadyuvantes glicolipidicas AR059192A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76227906P 2006-01-26 2006-01-26
US81498406P 2006-06-20 2006-06-20

Publications (1)

Publication Number Publication Date
AR059192A1 true AR059192A1 (es) 2008-03-12

Family

ID=38309580

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100334A AR059192A1 (es) 2006-01-26 2007-01-25 Composiciones coadyuvantes glicolipidicas

Country Status (20)

Country Link
US (1) US8460679B2 (es)
EP (2) EP2481423A1 (es)
JP (1) JP5538725B2 (es)
KR (2) KR20110140140A (es)
AR (1) AR059192A1 (es)
AU (1) AU2007209104B2 (es)
BR (1) BRPI0706709B8 (es)
CA (1) CA2634888C (es)
CY (1) CY1114310T1 (es)
DK (1) DK1991266T3 (es)
ES (1) ES2425576T3 (es)
ME (3) ME00045B (es)
NO (1) NO341463B1 (es)
NZ (1) NZ569375A (es)
PL (1) PL1991266T3 (es)
PT (1) PT1991266E (es)
RS (2) RS20080318A (es)
RU (1) RU2392965C2 (es)
TW (1) TWI372631B (es)
WO (1) WO2007085962A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2040745B1 (en) * 2006-06-28 2012-12-05 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
WO2009156960A2 (en) * 2008-06-27 2009-12-30 Pfizer Inc. Novel adjuvant compositions
BRPI0920800A2 (pt) 2008-10-03 2020-08-11 Novartis Ag vírus da herpes bovina-1, composição, método para produzir uma resposta imunológica em um hospedeiro, e, uso de vírus da herpes bovina-1.
ES2743465T3 (es) * 2013-03-15 2020-02-19 Glaxosmithkline Biologicals Sa Composición que contiene derivados fosfato de aminoalquil glucosaminida tamponados y su uso para potenciar una respuesta inmunitaria
UA121200C2 (uk) 2013-09-19 2020-04-27 Зоетіс Сервісіз Ллс Ад'ювант на основі олії
US11318200B2 (en) 2013-11-26 2022-05-03 Zoetis Services Llc Methods and compositions for induction of immune response
EP4248992A3 (en) 2015-01-16 2023-12-27 Zoetis Services LLC Foot-and-mouth disease vaccine
KR102085968B1 (ko) * 2015-07-20 2020-03-06 조에티스 서비시즈 엘엘씨 리포솜 보조제 조성물
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
CN110713520B (zh) * 2019-11-06 2021-01-01 中国石油天然气股份有限公司 油酰基氨基酸-γ-L-谷氨酰-L-半胱氨酰-甘氨酸多肽及其制备与应用
TWI884296B (zh) 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
WO2022072431A1 (en) 2020-09-30 2022-04-07 Zoetis Services Llc Novel pasteurella multocida strains and vaccines having hyac and nanp deletions
CN121360223A (zh) 2024-07-19 2026-01-20 硕腾服务有限责任公司 流感疫苗

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291019A (en) * 1979-07-09 1981-09-22 Iowa State University Research Foundation, Inc. Vaccine for infectious bovine rhinotracheitis
DE3213650A1 (de) 1982-04-14 1983-10-27 Bayer Ag, 5090 Leverkusen N-glycosylierte carbonsaeureamid-derivate, verfahren zu ihrer herstellung sowie ihre verwendung zur beeinflussung der koerpereigenen abwehr
DE3403495A1 (de) 1983-11-23 1985-05-30 Bayer Ag, 5090 Leverkusen Phosphorylierte glycosylamide, -harnstoffe, -carbamate und -thiocarbamate, verfahren zu ihrer herstellung sowie ihre verwendung
DE3346623A1 (de) 1983-12-14 1985-07-04 Bayer Ag, 5090 Leverkusen N-glycosylierte harnstoffe, carbamate und thiocarbamate, verfahren zu ihrer herstellung sowie ihre verwendung
DE3521994A1 (de) * 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
NZ232740A (en) * 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US6764682B1 (en) * 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
US5718904A (en) 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US6290971B1 (en) 1995-06-15 2001-09-18 Aventis Pasteur Limited Adjuvant compositions comprising a mineral salt and another immunostimulating compound
FI109332B (fi) * 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
MXPA03002890A (es) * 2000-10-02 2004-12-03 Glaxosmithkline Biolog Sa Preparacion de virus con envolvente dividido.

Also Published As

Publication number Publication date
JP2009524638A (ja) 2009-07-02
WO2007085962A2 (en) 2007-08-02
MEP4508A (en) 2010-06-10
ES2425576T3 (es) 2013-10-16
NO341463B1 (no) 2017-11-20
NO20083405L (no) 2008-10-23
BRPI0706709B1 (pt) 2021-03-23
ME00045B (me) 2010-10-10
TW200738268A (en) 2007-10-16
CY1114310T1 (el) 2016-08-31
NZ569375A (en) 2010-05-28
DK1991266T3 (da) 2013-08-26
US20070196384A1 (en) 2007-08-23
TWI372631B (en) 2012-09-21
RS52930B (sr) 2014-02-28
CA2634888C (en) 2016-06-21
ME01545B (me) 2014-04-20
EP1991266B1 (en) 2013-06-26
BRPI0706709B8 (pt) 2021-05-25
PT1991266E (pt) 2013-08-28
EP1991266A2 (en) 2008-11-19
US8460679B2 (en) 2013-06-11
BRPI0706709A2 (pt) 2011-04-05
WO2007085962A3 (en) 2007-12-27
CA2634888A1 (en) 2007-08-02
RS20080318A (sr) 2009-05-06
KR101202553B1 (ko) 2012-11-20
AU2007209104B2 (en) 2010-04-08
AU2007209104A1 (en) 2007-08-02
PL1991266T3 (pl) 2013-11-29
KR20110140140A (ko) 2011-12-30
RU2008129203A (ru) 2010-03-10
EP2481423A1 (en) 2012-08-01
HK1128078A1 (en) 2009-10-16
JP5538725B2 (ja) 2014-07-02
RU2392965C2 (ru) 2010-06-27
KR20080080223A (ko) 2008-09-02

Similar Documents

Publication Publication Date Title
AR098830A2 (es) Suspensiones acuosas estabilizadas para administración parenteral
ES2339187T3 (es) Procedimiento de fabricacion de composiciones tensioactivas concentradas.
RU2496467C2 (ru) Композиции, пригодные для отбеливания зубов
ES2303703T3 (es) Composicion tensioactiva.
RU2016109925A (ru) Адъюванты на масляной основе
ES2639115T3 (es) Uso de monoésteres de isosorbida como espesante
RU2008129203A (ru) Новые гликолипидные адъювантные композиции
PE20060291A1 (es) Composiciones farmaceuticas inyectables de posaconazol con particulas estabilizadas
BRPI0214794B8 (pt) sistema para melhorar a saúde da pele de usuários de artigo absorvente.
PE20071310A1 (es) Formulaciones liquidas de fenilefrina
RU2008138646A (ru) Жидкая композиция g-csf
DOP2012000064A (es) Formulaciones farmaceuticas muy concentradas
BR0211736A (pt) Formulação para suspensão oral estabilizada
PE20120319A1 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no ionico
AR076778A1 (es) Composiciones orales que contienen compuestos de poliguanidinio y metodos de preparacion y uso de las mismas
JP6393821B1 (ja) 紙類処理剤
AR081364A1 (es) Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
ES8608888A1 (es) Una formulacion parenteral endoparasiticida y ectoparasiticida
PE20070437A1 (es) FORMULACION ACUOSA hFSH
AR123110A1 (es) Vacunas anticoronavirus
CL2009000779A1 (es) Composicion de suspension pesticida acuosa que comprende ciazofamid, un agente tensioactivo de organosilicona, un agente reductor de la viscosidad, un agente anti-espumante, un agente para ajuste del ph y un dispersante.
KR970706839A (ko) 성장호르몬 및 이소루신으로 이루어진 약학적 조성물(a pharmaceutical formulation comprising a growth hormone and isoleucine)
PE3096A1 (es) Formulacion conteniendo selenio
AR105393A1 (es) Composiciones adyuvantes liposómicas
ES2647770T3 (es) Composición para aplicación externa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal